Search Results

You are looking at 121 - 130 of 143 items for :

  • Refine by Access: All x
Clear All
Full access

platform allows us to make vital cancer information more accessible than ever, as we adjust for the ongoing COVID-19 pandemic,” explained Robert W. Carlson, MD, Chief Executive Officer, NCCN. “We look forward to having attendees from around the world and

Full access

Noël Arring, Christopher R. Friese, Bidisha Ghosh, Marita Titler, Heidi Hamann, Sanja Percac-Lima, Adrian Sandra Dobs, Michelle J. Naughton, Pooja Mishra, Melissa A. Simon, Bingxin Chen, Electra D. Paskett, Robert J. Ploutz-Snyder, Martha Quinn, and Debra L. Barton

group of participants may or may not have coincided with the completion of an intervention for an individual participant. Data for 2020 were collected at the start of 2021. These data were impacted by the first year of the COVID-19 pandemic. In

Full access

Network, Plymouth Meeting, PA; 7 University of Washington Medical Center, Seattle, WA Introduction: The use of telemedicine in the oncology (Onc) setting expanded after March 2020 due to the COVID-19 pandemic. Patients and providers report satisfaction

Full access

The Cancer Center Cessation Initiative Implementation Science Working Group

treatment sustains during COVID-19, a global pandemic [published online August 18, 2021] . Cancer Epidemiol , doi: https://doi.org/10.1016/j.canep.2021.102005 34446379 13. Jose T , Ohde JW , Hays JT , Design and pilot implementation of

Full access

Presenters: Lillian R. Kreppel, Shivan J. Mehta, Mark H. Sawyer, Edward L. Trimble, Susan T. Vadaparampil, and moderated by Wui-Jin Koh

infrastructure for administering it, societal and parental resistance to the vaccine, and misinformation spread through social media. The COVID-19 pandemic has added another challenge by delaying all immunizations, Dr. Trimble reported. Finally, there are

Full access

Presenter: Natalie S. Callander

antibody therapy, Dr. Callander recommended changing either the PI, the IMiD, or both. Using an oral triplet regimen is another consideration during the COVID-19 pandemic in order to limit in-person visits. There are phase III data supporting the

Full access

important in light of the COVID-19 pandemic, which has seen reduced screening numbers, which are projected to result in increased late-stage diagnoses. More on NCCN’s message that “Cancer Won’t Wait and Neither Should You” can be found at NCCN

Full access

Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu

-specific mortality. It is well-known that elevated circulating CEA levels can also be found in some benign statuses and inflammation-derived diseases, such as COVID-19, 39 , 40 and the specificity of CEA for diagnosing primary gastrointestinal tumors is limited

Full access

comparable age, and 13% preferred someone of their own gender. One patient was unable to fill out baseline surveys due to worsening of their medical condition. Due to the COVID-19 pandemic, the trial was closed for the eight months but is now open to accrual

Full access

Alex J. Ball, Imran Aziz, Sophie Parker, Ravishankar B. Sargur, Jonathan Aldis, and Matthew Kurien

generated controversy and been used to mitigate pressure on endoscopic and radiologic resources, which have been impacted by the COVID-19 pandemic. 20 Future work needs to evaluate this evolving use of FIT to ensure appropriate triaging and prioritization